EuroSciCon

Nano Drug Delivery 2018

August 16-17

Dublin, Ireland



Nano Drug Delivery

http://nano-drugdelivery.euroscicon.com/

EuroSciCon

12th Edition of International Conference on

Nanopharmaceutics and Advanced Drug Delivery

DATE & VENUE

16-17 AUGUST 2018 | DUBLIN, IRELAND

AGENDA

Biography

EuroSciCon

Title: Smart combination nanopreparations for cancer: bringing drugs inside cells and to individual organelles

Vladimir P. Torchilin
Northeastern University,
USA

Biography

Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 52,000 citations of his papers with H-index of 102. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.

Title: Bio-inspired anionic polymers as a platform for designing novel nanoscale intracellular drug delivery systems

Rongjun Chen
Imperial College
London, **UK**

Biography

Dr Rongjun Chen is Senior Lecturer in the Department of Chemical Engineering at Imperial College London. After obtaining his MSc degree in Materials Science from Tsinghua University in 2003, he studied for his PhD degree at Cambridge University during 2003 – 2007, with focus on polymer drug delivery. During Oct 2006 – Sep 2009, he carried out his postdoctoral research at Cambridge University first on lyophilisation of pharmaceuticals and then on manufacture of clinical-grade lentiviral vectors for gene therapy. From Oct 2009 – Apr 2013, he started his independent academic career by taking a tenure-track faculty position as the Group Leader and BHRC Senior Translational Research Fellow at the University of Leeds. In May 2013, he moved to Imperial College London as a Lecturer and was promoted to Senior Lecturer in 2016. His research interests focus on biomaterials, nanomedicine, drug delivery and cell therapy.

Title: Attenuated Protein Toxins as Intracellular Nucleic Acid Delivery Vectors

Simon C. W. Richardson
University of
Greenwich, **UK**

Biography

Dr Richardson is a founder, director and CSO at Intracellular Delivery Solutions Ltd (www.IDS.bio), and Reader (Associate Professor) in Membrane Trafficking and Drug Delivery, at the University of Greenwich, UK. The driving theme behind my research is the intracellular delivery of antisense and RNAi to the cytosol. I am currently leading the Cell Biology Research Cluster within the Faculty of Engineering and Science, located at the Medway campus about 40 miles outside of London. My lab is currently working with several technologies based upon attenuated virulence factors that have very low in vitro toxicity profiles (and are minimally disruptive to the cell), and very high efficiency intracellular delivery profiles. We are also examining several methodologies to modulate protein stability and intracellular trafficking to aid the oral delivery of vaccines.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: CodeSphere - Molecular encoding of nanoparticles for targeted cargo delivery

Keith H Moss
University of Cape Town, **Denmark**

Biography

Keith Moss holds a BSc in Biochemistry and Genetics from the University of Cape Town and an MSc in Engineering in Biotechnology from the Technical University of Denmark (DTU). Now, as a first year PhD student at DTU, Keith is engaged in the development of a novel technology platform for the identification of optimal nanoparticles for therapeutic applications. This project encompasses multiple disciplines and incorporates Keith's interest in human disease and molecular therapeutics as well as nanotechnology and pharmaceutical drug development.

Title: Anticancer Activity of G rich Aptamer AS1411 grafted to Gold nanospheres: From Synthesis to Mechanism Study

samaneh kabirian dehkordi
University of Isfahan, **France**

Biography

Samaneh KABIRIAN has her expertise in synthesis, characterization of nanoparticles conjugated to aptamers. and passion in improving its application in biology of cancer. Basically she is chemist and she finished her bachelor in pure chemistry and her master in analytical chemistry in detection of biomolecule in blood. As she is always curious and enthusiastic to work on multidisciplinary project and bridging gap between different domains of science. She is now doing a double degree PhD in molecular and cellular biology at university of Lyon and in parallel Analytical chemistry at Isfahan university-Iran. 3 years studying and working in biochemistry and biology laboratory of cancer research center of Lyon-France gave her a good point of view to biological aspects of applications of Nanoparticles in biology of cancer. With her strong background in chemistry and specially analytical chemistry, She is also trained in all common molecular and cellular biology manipulations like Cell culture, Protein and DNA analysis and so on . Her double skilled ability can build a good connection in multidisciplinary project especially cancer biology and pharmaceutical chemistry.

Title: Phosphonium carbosilane dendrimers: Efficient non-viral vectors for siRNA delivery to adenocarcinoma cells in vitro

Regina Herma
university of jan evangelista purkyne, **Czech Republic**

Biography

Regina Herma is PhD candidate and her work is mainly focused on the effect of type, generation and surface modification of carbosilane dendrimers on the interaction with selected nucleic acids for applications in biomedicine (transport molecules for drug targeting, vectors for gene therapy, potential treatment of lung cancer). She is part of a research team for a number of projects.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: Immunoliposomes containing simvastatin, targeted towards EGFR, as potential therapeutic for a treatment of EGFR-dependent breast cancer tumors.

LucynaMatusewicz
University of Wroclaw,
Poland

Biography

LucynaMatusewicz is aPhD student at University of Wroclaw.Lucyna graduated with MSc in biotechnology in 2012. After graduation she started her PhD project and

for almost 6 years she focuses mainly on drug delivery systems in anticancer therapy.

Title: Controlled Release of Bovine Serum Albumin from Surfactant Modified Alginate Beads

Nilay Kahya
Istanbul Technical University
Turkey

Biography

Nilay Kahya is a Ph.D. candidate working under the guidance of Prof. F. Bedia Erim Berker. She completed her MSc degree in Chemistry at ITU Graduate School of Science Engineering and Technology in 2016. Research fields of her are mainly related to the applications of biopolymers in drug delivery systems and adsorption fields. She has four publications in Science Citation Index Expanded journals by March 2018.

Title: Antibody-Proteases as a Novel Biomarker and a Unique Target to suit Translational Tools to be applied for Biodesign, Bioengineering and Regenerative Medicine.

Sergey Suchkov
Sechenov University
Russia

Biography

Sergey Suchkov graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his PhD at the I.M. Sechenov Moscow Medical Academy and in 2001, maintained his Doctorship Degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI. Dr Suchkov has been trained at: NIH; Wills Eye Hospital, PA, USA; Univ of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He is a member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); PMC (Personalized Medicine Coalition), Washington, USA.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: Major role of complement activation compared to protein corona composition in the capture of stealth-NP by phagocytes: inter-individual and inter-species variability

Emanuele Papini
University of Padua,
Italy

Biography

During my career I have worked on several aspects of bio-medicine: the biochemical base of O2.- production in phagocytes, the action mechanism and cell selectivity of bacterial toxins and adhesins, natural and artificial peptides and foldamers. I gave important contribution to the understanding of the mechanism of cellular intoxication by diphtheria toxin and the vacuolating toxin from H. pylori. Later, I characterized the interaction of N. meningitidis adhesin and anti-menB vaccine component NadA with immune cells. Eventually, I got interested in nanoparticles, investigating their possible application in cancer targeting and other central issues related to nanomedicine. Specifically, I study the functional role of plasma NPs-interacting proteins in phagocyte clearance, including the coagulation and the complement systems and their cross-talk, and the possible modulation of NPs adverse reactions by pathogens or commensals PAMPs. My ambition is to provide critical information useful for the rationale design of nanoparticles for effective biomedical use.

Title: Apoferritin cage nanostructure as the anthracycline delivery system

Katarzyna Kurzatkowska
Department of Biosensors,
Poland

Biography

Katarzyna Kurzatkowska received her Ph.D. degree in chemistry in 2009 from the Department of Chemistry of Nicolaus Copernicus University in Torun, Poland. She holds a position of assistant professor at Department of Biosensors in the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn. From 18 October 2009 to 17 October 2010, she was worked as a Marie Curie fellow at the Department of Biophysical Chemistry and Molecular Oncology in the Institute of Biophysics Academy of Sciences of the Czech Republic, in laboratory of Prof. Emil Paleček. She was on postdoctoral position at the Department of Chemistry, State University of New York at Potsdam, NY, USA. in laboratory of prof. Maria Hepel in 2015 and 2017. Her current interests have been focused on developing theranostic targeted drug delivery nanocarriers.

Title: Synthetic Derivatives of Porphyrins as Potential Anticancer Agents

Jan Habdas
University of Silesia,
Poland

Biography

Jan Habdas has received his PhD in 1978 from the University of Silesia, Department of Chemistry, Katowice, Poland. He was a Postdoctoral fellow and a Research Associate at Texas Tech University, Kansas State University and University of Idaho. Since 1990, his main scientific interest has been the synthesis of porphyrins in the aspects of their applications in cancer therapy. He has synthesized a new group of porphyrin derivatives: Phosphono-aminepeptidyl porphyrins. He has published 62 papers in major peer reviewed reputable chemical, biochemical and medical journals; among them 42 are on synthesis of photochemical and medical properties of porphyrins.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: The Use of Flow Imaging Microscopy for Nanoparticle Analysis in Biopharmaceuticals

Kent Peterson
Fluid Imaging Technologies,
USA

Biography

Kent Peterson has lead Fluid Imaging Technologies since joining the founder over 12 years ago. The Company has sold over 600 FlowCams in over 52 countries. Ship-based FlowCam systems have also been at work sampling from every ocean in the world. Mr. Peterson has served on a number of boards and is active in community affairs. He has also been named Mainebiz Business Leader of the Year. Fluid Imaging Technologies' awards and recognitions include, the Governor's Award for Business Excellence, the S.B.A. New England Exporter of the Year award, and the Portland Regional Chamber's Robert R. Masterton Award. Mr. Peterson is an honors graduate from Boston University's Graduate School of Management, and a member of American Mensa Society.

Title: Multi-functional magneto-liposomes for photo-thermally triggered drug release and MRI imaging

Wafa T. Al-Jamal
Queen's University Belfast,
UK

Biography

Dr Wafa Al-Jamal completed her PhD in Drug Delivery in 2008 at UCL School of Pharmacy, London. She is currently a Reader in Nanomedicine and Drug Delivery at Queen's University Belfast, School of Pharmacy. She is also a Prostate Cancer Research Fellow. Wafa joined the University of East Anglia as a Lecturer in Drug Delivery (2013-2017), after working as a Senior Research Fellow at University College London and King's College London (2008-2013). Dr Al-Jamal's multidisciplinary team works on developing novel nanomedicines for combinatory therapy and theranostic applications. Currently, her research focuses on developing smart vectors for delivering a broad range of therapeutic agents, and to fabricate multifunctional nanoparticles to target cancer and other diseases. Her long-term research career is to facilitate the translation of nanoparticle-based therapeutics from the lab to the clinic.

Title: Developing targeted liposomal vaccines.

Yvonne Perrie
University of Strathclyde,
UK

Biography

Prof Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. In 1998 she gained her PhD from the University of London investigating the role of liposomes for drug delivery. Yvonne then worked in London within a newly established Drug Delivery Company (Lipoxen Technologies Ltd) for two years, developing their liposome drug delivery platform technology prior to moving into Academia to set up her own research group. Yvonne joined Aston University in 2000 and was appointed Professor in Drug Delivery in 2007. In 2016, Yvonne moved to the University of Strathclyde as Professor in Drug Delivery as part of the Global Talent Appointment Programme. Yvonne's research is multi-disciplinary and is focused on the development of drug delivery systems to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare problems.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: Fennel 3 - A Novel Natural Remedy for Mild and Chronic Constipation

Rafie Hamidpour
Pars Bioscience Research Center,
USA

Biography

Dr. Rafie Hamidpour is president and CEO at the Pars Bioscience Research center and the director of the Herbal Medicine Laboratory at this institute. He is a traditional cancer scientist focusing on intervention with Traditional medicinal and pharmacology of herbal medicine in order to treat human tumor that invades surrounding tissue and may spread to distant parts of the body by way of the lymphatic or circulatory system. Therapeutic targets which are identified to be Cancer-Specific will be pursued by both gene and drug therapy methods by Dr. Hamidpour's team towards designing a comprehensive genetics the process by which information in messenger RNA directs the sequence of amino acids assembled by a ribosome during protein synthesis Transcriptional targeting of an oncolytic virus is a virus that preferentially infects and kills cancer cells as the infected cancer cells are destroyed by lysis Viruses is a major focus of research, as the most important pro-oncogenic signaling pathway involved in genetics the first step in the replication of a retrovirus following its infection of a living cell, in which its genetic code is transferred from RNA to a molecule of DNA

Title: Nanotheranostics: TPGS micelles for early diagnosis and therapy of cancer

MUTHU MADASWAMY SONA
IIT (BHU),
India

Biography

M.S. Muthu earned Bachelor Degree in Pharmacy in 2002, Master's in Pharmaceutical Technology from India in 2004 and Ph.D. degree in Pharmaceutics from IIT, Varanasi, India in 2009. He did his postdoctoral trainings in Department of Chemical Engineering at National University of Singapore as a recipient of BOYSCAST Fellowship and CREST Award from India. He is also an awardee of DST Young Scientist in 2012. Muthu's research interest is to develop advanced nanomedicine as novel platform for diagnosis and therapy. He has authored over 64 peer-reviewed publications with a cumulative impact factor of >240, citation of 2100 and h-Index of 24.

Title: Optimizing trnsfection of primary human umbilical vein endothelial cells using facial amphipathic deoxycholic acid-conjugated polyethyleneimine

Fatemeh Radmanesh
University of Medical Sciences
Iran

Biography

Fatemeh Radmanesh is a member of Royan Cardiovascular and Cell Engineering Groups. She studied Biotechnology in her BSc and

graduated in MSc of Microbial Biotechnology from Isfahan University. Now, she is PhD student of Medical Biotechnology at Shahid Beheshti

University of Medical Sciences. She is interested in nanoparticulate delivery strategies, specially for RNAi-based therapeutics delivery. She

joined Royan Institute at 2015 to do her PhD thesis on using polymeric nanoparticles to deliver RNAi therapeutics.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: Nanomedicine: from high tech to global health

Robert K. Prud'homme
Princeton University
USA

Biography

Robert Prud'homme is a professor in the Department of Chemical and Biological Engineering at Princeton University. He is the founding director of the Program in Engineering Biology. His research program focusses on polymer self-assembly applied to drug delivery. The development of Flash NanoPrecipitation (FNP) in his laboratory enabled the encapsulation of poorly soluble drug compounds and oligonucleotides for therapy directed towards cancer, TB, and injections. FNP is a scalable and continuous process that is enables integrated processing and spray drying for low cost oral and aerosol formulations. Under sponsorship by the Bill and Melinda Gates Foundation, the process is being adopted to formulate new compounds coming from TBA, MMV, and DNDi.

Title: Encapsulation of nanoparticles in composite gel microparticles for lung imaging and drug delivery

Robert K.Prud'homme
Princeton University
USA

Biography

Robert Prud'homme is a professor in the Department of Chemical and Biological Engineering at Princeton University. He is the founding director of the Program in Engineering Biology. His research program focusses on polymer self-assembly applied to drug delivery. The development of Flash NanoPrecipitation (FNP) in his laboratory enabled the encapsulation of poorly soluble drug compounds and oligonucleotides for therapy directed towards cancer, TB, and injections. FNP is a scalable and continuous process that is enables integrated processing and spray drying for low cost oral and aerosol formulations. Under sponsorship by the Bill and Melinda Gates Foundation, the process is being adopted to formulate new compounds coming from TBA, MMV, and DNDi.

Title: Indian Solution to Global Health Promblems via New Nano-Biotech Immunity Drug: Receptol

Pawan Saharan
Biomix Network Limited
India

Biography

Dr. Pawan Saharan, with a vision to provide Health for all, Invented World's 1st Immunity Enhancement Drug to treat HIV and host of other Immunity problems via Broad Spectrum Antiviral and New Generation Immuno-modulator- RECEPTOL®. Dr. Saharan as a World Leader in healthcare industry responsible for changing the destiny of nations & human race via the creative contribution in the healthcare sector via Receptol that builds body's own immune system, providing hope to most disenchanted terminally ill patients globally. Dr. Saharan created the first truly Nano-Bio-IT Helix via inventing Radha 108 Nano-Peptides for AIDS therapy : RECEPTOL® along with reusable micro-chip diagnostics for AIDS, Cancer, TB and other infections, costing a fraction of current tests creating a paradigm shift in healthcare & bringing smile on Billion Faces who could not afford modern treatment.

SPEAKER SLOTS AVAILABLE

Biography

EuroSciCon

Title: Novel layered double hydroxide nanoplatform as ultrasensitive t1 – mri contrast agent and theranostic agent for mice tumor diagnosis and complete treatment

Ms. Bei Li
University of Queensland
Australia

Biography

2015.7- present: PhD student at The University of Queensland, specializes in Layered Double Hydroxide-based Nanoparticles as Multifunctional Theranostic Agents

for Cancer Treatment, under the supervision of Prof Zhi Ping (Gordon) XU.

Title: Lipid coated calcium carbonate/phosphate nanoparticles as a novel gene/drug co-delivery platform for cancer treatment

Ms. Yilun Wu
Cnr College
Australia

Biography

Yilun Wu has her expertise in nanodelivery preparation in improving cancer treatment efficacy, especially melanoma immunotherapy by silencing PD-L1 related genes. Conventional treatments of melanoma, such as chemotherapy and radiotherapy, can cause some severe side effects. So finding an efficient treatment for late stage melanoma is of great importance, where immunotherapy is one of the promising approaches. To overcome tumour tolerance to the immune system, one effective approach is to suppress the programmed cell death ligand-1 (PD-L1) with siRNAs. Herein, LCCP NPs are designed as novel siRNA delivery platforms for knockdown of PD-L1 gene and/or upstream genes. Successfully completing this project may provide a novel nanoparticle-based siRNA delivery approach for melanoma immunotherapy.

SPEAKER SLOTS AVAILABLE

Past Affiliates

Balint Sinko
Pion Inc, USA

Dimitrios A Lamprou
University of Kent, UK

Khaled Greish
Arabian Gulf University, Bahrain

Volkmar Weissig
Midwestern University College of Pharmacy Glendale, USA

Wafa T Al-Jamal
University of East Anglia, UK

Katja Bettina Ferenz
University of Duisburg-Essen, Germany

Volkmar Weissig
World Mitochondria Society, USA

Sharif Abdelghany
University of Jordan, Jordan

Barbara Palazzo
Ghimas SpA c/o Dhitech Scarl, Campus Ecotekne, Italy

Tatiana Hurtado de Mendoza
Sanford Burnham Prebys Medical Discovery Institute, USA

Olivia Merkel
Ludwig-Maximilians-Universität München, Germany

Ruba Ismail
University of Szeged, Hungary

Shilpa Raut
Amway, USA

Marco Contardi
Italian Institute of Technology, Italy

Annalisa Dalmoro
University of Salerno, Italy

Drazen Raucher
University of Mississippi Medical Center, USA

Fatma Demir Duman
Koc University, Turkey

Abdulrahman M Elbagory
University of the Western Cape, South Africa

Paul Fisher
Inovio Pharmaceuticals Inc, USA

Maria Manuela Gasper
University of Lisboa, Portugal

Nicole R S Sibuyi
University of Western Cape, South Africa

Jim Jingjun Huang
Ascendia Pharmaceuticals, USA

Fanzhu Li
Zhejiang Chinese Medical University, China

Congcong Lin
Hong Kong Baptist University, Hong Kong

Kyle M Jandrasitz
Microfluidics International Corporation, USA

Zaheer Ahmad
Chinese Academy of Sciences, China

Xue Zhang
Hong Kong Baptist University, Hong Kong

Cristina M Sabliov
Louisiana State University, USA

Peter Krajcsi
Solvo Biotechnology, Hungary

Julia Ernst
Friedrich Schiller University Jena, Germany

A J Mixson
University of Maryland School of Medicine, USA

Felix Kratz
CytRx Corporation, Germany

Pegah Esmaeilzadeh
Martin Luther University of Halle-Wittenberg, Germany

Yan He
Sanofi Aventis Group, USA

Costas Kiparissides
Aristotle University of Thessaloniki, Greece

Sophie Franceschi
Université Paul Sabatier, France

Byeongwoon Song
University of California, Davis, USA

Zeeshan Ahmad
De Montfort University, UK

Hiroshi Maeda
Sojo University, Japan

Dong Seok Kim
NIH, USA

Maria Manuela Gasper
University of Lisbon, Portugal

Damon Smith
Altus Formulation Inc, Canada

Past Affiliates

Alessandro Parodi
Houston Methodist Research Institute, USA

Fabienne Danhier
Louvain Drug research Institute, Belgium

Christophe A Serra
CNRS Institut Charles Sadron, France

Amanda E Brooks
North Dakota State University, USA

Gary Gellerman
Ariel University, Israel

Reinhard Gabathuler
biOasis Technologies Inc, Canada

Matthew N Bahr
GlaxoSmithKline, USA

Yücel Baspinar
Ege University, Turkey

Mariusz Skwarczynski
University of Queensland, Australia

Maria Principia Scavo
University of Kentucky, USA

Nashiru Billa
University of Nottingham, Malaysia

Yingqing Ran
Genentech, Inc USA

Irach B Taraporewala
Sitara Pharmaceutical Group, USA

B B Barik
Jazan University, KSA

Omathanu Perumal
South Dakota State University, USA

Joe Jensen
NOBLE , USA

Ruchi Bansal
University of Twente, Netherlands

Stefaan De Koker
Ghent University, Belgium

Subhash C Chauhan
University of Tennessee Health Science Center, USA

Nermin Salah Ahmed
University in Cairo, Egypt

Xing-Jie Liang
Chinese Academy of Sciences, China

Kristen K Comfort
University of Dayton, USA

Joel Richard
IPSEN, France

Tais Gratieri
University of Brasilia, Brazil

Adriana Avila Flores
Auburn University, USA

Kang Choon Lee
SungKyunKwan University, South Korea

Shunichi Sato
National Defense Medical College, Japan

Tatiana Samoylova
Auburn University, USA

Gabriele Sadowski
TU Dortmund, Germany

Arik Dahan
Ben-Gurion University of the Negev, Israel

Irach B Taraporewala
Sitara Pharmaceutical Group, USA

Tina Kauss
University of Bordeaux, France

Amitava Das
CSIR-IICT, India

Rajiv Nayar
HTD Biosystems, USA

Mino R Caira
University of Cape Town, South Africa

Chunsheng Gao
Beijing Institute of Pharmacology and Toxicology, China

Charles O Noble
ZoneOne Pharma, USA

Alessandra Maroni
University of Milan, Italy

Blessing Aderibigbe
University of Fort Hare, South Africa

Mitra Mosharraf
HTD Biosystems, USA

Peter O'Connell
Trinity College Dublin, Ireland

Ndidi Ngwuluka
University of Jos, Nigeria

Aryo Sorayya
Engimata Inc, USA

Gillian Hutcheon
Liverpool John Moores University, UK

Kazuya kikuchi
Osaka University, Japan

Past Affiliates

Ruxana T Sadikot
Emory University School of Medicine, USA

Shayan F Lahiji
Yonsei University, South Korea

Noha Nafee
Alexandria University, Egypt

Arti R Thakkar
Eshelman School of Pharmacy, USA

Chinnathambi Shanmugavel
National Institute for Materials Science, Japan

Hajime Mori
Kyoto Institute of Technology, Japan

M N V Ravi Kumar
Texas A&M Health Science Center, USA

Rafael Bernad
Bicosome SL, Spain

Shashi Ravi Suman Rudrangi
Bristol Laboratories, United Kingdom

Alessandro Grattoni
Houston Methodist Research Institute, USA

Ana Rute Neves
University of Porto, Portugal

Philippe Bertrand
University of Poitiers, France

Mansi K Shah
Amneal Pharmaceuticals, USA

Vanessa Gonçalves
iBET, Portugal

Ulo Langel
Stockholm University, Sweden

Simi Gunaseelan
University of Texas, USA

Benedetta Santini
University of Milano-Bicocca, Italy

Goldie Oza
CINVESTAV-IPN, Mexico

Steven A Giannos
Independent Consultant, USA

Sahar Awwad
UCL School of Pharmacy, UK

Hidetoshi Arima
Kumamoto University, Japan

Hussaini Syed-Sha-Qhattal
DPT Laboratories, USA

Olga Gawrys
Mossakowski Medical Research Centre PAS, Poland

Miguel Gama
Minho University, Portugal

William Ying
Bristol Myers Squibb, USA

Merari Chevalier
CoMP-INTEMA- Universidad
Nacional de Mar del Plata, Argentina

Yaping Li
Chinese Academy of Sciences, China

Bulent Ozpolat
The University of Texas-MD Anderson Cancer Center, USA

Meliha Ekinci
Ege University, Turkey

Giovanni Filippo Palmieri
University of Camerino, Italy

Mandip Singh
Florida A&M University, USA

Jesus Izaguirre Carbonell
Tokyo University of Science, Japan

Ahmed Abdelfattah Hafez Abdellatif
Azhar University, Egypt

Joe Jensen
Noble, USA

Catarina Duarte
IBET, Portugal

Hyungil Jung
Professor, Yonsei University, South Korea

Mitra Mosharraf
HTD Biosystems Inc, USA

Luisa Fiandra
University of Milan, Italy

Andrea L Armstead
Precision Nanosystems, Inc BC

Michael O Rourke
Scotia Vision Consultants, USA

Havazelet Bianco-Peled
Technion–Israel Institute of Technology, Israel

Alessandro Parodi
Houston Methodist Research Institute, (HMRI-Houston) USA

Pamela Davol
Ximedica, USA

Abdelazim Zaghloul
Kuwait University, Kuwait

Dong Hee Kim
Sungkyunkwan University, Korea

Xinyuan Chen
Massachusetts General Hospital, USA

Helen McCarthy
Queen's University Belfast, Northern Ireland

Cristiana de Azevedo
Universidade Nova de Lisboa, Portugal

Steve Hood
GSK, UK

José Crecente Campo
Center for Research in Molecular
Medicine and Chronic Diseases (CIMUS), Spain

Shukai Ding
University of Strasbourg, France

Steve Rannard
University of Liverpool, UK

Fatmah Alasmary
King Saud University, Saudi Arabia

Heba A Hazzah
Alexandria University, Egypt

Achim Aigner
Leipzig University, Germany

Stephen Loughran
Queens University Belfast, Northern Ireland

Seth Pincus
Children's Hospital and LSU School of Medicine,USA

Fiorenza Rancan
Universitätsmedizin Berlin, Germany

Hinojal Zazo Gamez
Universidad of Salamanca, Spain

Md Zaidul Islam Sarker
International Islamic University, Malaysia

Patrizia Chetoni
University of Pisa, Italy

Shrawan Baghel
Waterford Institute of Technology, Ireland

El Refaie Kenawy
Tanta University, Egypt

Christine Dufès
University of Strathclyde, UK

Muhammad Irfan Alam
University of Sunderland, UK

Mohammad Refaat Khattab
Cairo University, Egypt

Hyungil Jung
Yonsei University, South Korea

Anton Aleksashkin
Lomonosov Moscow State University, Russia

Hidetaka Akita
Hokkaido University, Japan

Amiram Goldblum
The Hebrew University of Jerusalem, Israel

Istvan Toth
The University of Queensland, Australia

Saravanan Muniyandy
Monash University, Malaysia

Andreas Bernkop-Schnürch
University of Innsbruck, Austria

Hong Qi Zhang
Hong Kong Baptist University, China

Laili Che Rose
Universiti Malaysia Terengganu, Malaysia

Flavia Laffleur
University of Innsbruck, Austria

Marina V Zueva
Moscow Helmholtz Research Institute of Eye Diseases, Russia

Nobuhito Shibata
Doshisha Women's College of Liberal Arts, Japan

António José Ribeiro
University of Coimbra, Portugal

Katharina M Fromm
University of Fribourg, Switzerland

Samer R Abulateefeh
The University of Jordan, Jordan

Serena Mazzucchelli
University of Milan, Italy

Helen O McCarthy
Queen's University Belfast, UK

Russell G Burge
Freeslate, Inc USA

Victoria Sherwood
University of Dundee, UK

Christine Charrueau
Université Paris Descartes, France

Shinya Uchida
University of Shizuoka, Japan

Dimitrios A Lamprou
University of Kent, UK

Seitaro Kamiya
Nagasaki International University, Japan

Nicholas C Obitte
University of Nigeria, Nigeria

Reno A L Leon
Structo Pte Ltd, Singapore

Gerardo Byk
Bar Ilan University, Israel

Yuma Yamada
Hokkaido University, Japan

Arwyn T Jones
Cardiff University UK

Sophia Hatziantoniou
University of Patras, Greece

Mircea Alexandru Mateescu
Université du Québec à Montréal, Canada

Raid Alany
Kingston University, UK

Tista Bagchi
University of Delhi, India

Bernard Vrijens
MWV Healthcare, Belgium

Sharareh Salar-Behzadi
Research Center Pharmaceutical Engineering GmbH, Austria

Sabrina Gioria
JRC- European Commission, Directorate F – Health, Consumers and Reference Materials, Italy

Mark Cresswell
Lucideon, UK

Dagmar Fischer
Friedrich-Schiller University, Germany

Sandra Carvalho
University of Minho, Portugal

Shashi Ravi Suman Rudrangi
University of Greenwich, UK

Bruno Sarmento
University of Porto, Portugal

Francesca Ungaro
University of Napoli Federico II, Italy

Reenu Yadav
IES College of Pharmacy, India

Imran Saleem
Liverpool John Moores University, UK

Igor Chourpa
Université Francois Rabelais de Tours, France

Victor Lopez Davila
University College London, UK

Marta Truffi
University of Milano, Italy

Anne Grobler
North-West University, South Africa

Gintare Leonaviciute
University in Innsbruck, Austria

Satyanarayana Somavarapu
UCL School of Pharmacy, UK

Jonghwi Lee
Chung-Ang University, South Korea

Khuloud Al Jamal
King's College London, UK

Konstantinos Avgoustakis
University of Patras, Greece

Tourist Attractions at Dublin, Ireland









Tourist Attractions at Dublin, Ireland







